Clinical trials show that the hallucinogenic component of Magic Mushroom 'significantly improves depression with just one or two doses'

Research results have been announced that psilocybin , a hallucinogenic component of magic mushrooms , has 'an antidepressant effect that surpasses that of conventional psychotropic drugs.' Around the time of the publication of this treatise, Oregon announced that it was the first state in the United States to legalize psilocybin, and there is a growing movement to recognize the effects of psilocybin.

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial | Complementary and Alternative Medicine | JAMA Psychiatry | JAMA Network
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2772630

Clinical Trial Finds Substantial Antidepressant Effects From Psilocybin-Assisted Therapy
https://www.sciencealert.com/clinical-trial-finds-substantial-antidepressant-effects-from-psilocybin-assisted-therapy

New study finds psilocybin greatly and quickly relieves depression
https://www.psychnewsdaily.com/new-study-psilocybin-magic-mushrooms-relieves-depression/

Psilocybin contained in Magic Mushroom is being cracked down as a drug in many areas including Japan . On the other hand, several studies have shown that psilocybin has an effect on depression, and in 2019 the US Food and Drug Administration (FDA) announced that it has a major depressive disorder (MDD). ) Was approved as a breakthrough therapy .

The same hallucinogen ingredient as Magic Mushroom is approved by the authorities as a 'breakthrough therapy' for depression --GIGAZINE

Following these studies, a research team led by Alan Davis, a senior researcher at Johns Hopkins University, found the effects of psilocybin on 24 men and women aged 39.8 years on average who have suffered from MDD for an average of two years. Conduct clinical trials to confirm. Psilocybin was administered in two divided doses at intervals of about 5 hours in a total of 10 to 11 hours of psychotherapy, and the symptoms of depression were measured using the GRID Hamilton Depression Rating Scale (GRID-HAMD). did.

As a result, it was found that the GRID-HAMD score, which averaged 23 before administration of psilocybin, decreased to an average of 8 after administration. GRID-HAMD is diagnosed with 'severe depression' with a score of 24 or higher, 'moderate depression' with 17-23, and 'mild depression' with 8-16, so the score goes from 23 to 8. This result of a decrease means that 'people who were almost severely depressed have recovered to a level where they are diagnosed with mild depression.'

Regarding the results of this clinical trial, the research team wrote in a paper, 'The effect of treatment with psilocybin is about 2.5 times the effect seen with psychotherapy, and the effect of treatment with psychotropic drugs is about 2.5 times. It was more than four times the amount of effect seen in the study, suggesting that psilocybin given once or twice in supportive psychotherapy exerts a rapid and sustained antidepressant effect. I am. '

On November 4, 2020, the same day that Davis et al.'S study was published in the peer-reviewed medical journal JAMA Psychiatry, it was reported that 'Oregon became the first state to legalize hallucinogenic mushrooms.' It was . In Oregon, a referendum on Oregon Bill 109 , which allows the Oregon Department of Health to approve psilocybin treatment, was held on November 3, with a majority in favor. This makes it legal in Oregon to handle psilocybin in licensed facilities.

So far, cities such as Washington DC, Santa Cruz, California, Oakland, California, and Ann Arbor, Michigan have legalized magic mushrooms, but Oregon is the first to allow the use of psilocybin on a state-by-state basis. is.

A new area to decriminalize magic mushrooms appears --GIGAZINE